Compare Ginkgo Bioworks Holdings Inc (DNA) vs MasTec Inc (MTZ) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

MasTec (MTZ) trades at $216.11, down 3.25% on the day, with technical indicators showing a bearish trend as the stock trades below key moving averages. The company maintains strong fundamentals with revenue growth from $14.3B in 2025 to $16.1B projected for 2026, and net income improving to $494M. Recent news highlights MTZ's positioning in infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4B backlog.

The outlook remains positive given analyst consensus of 32 Buy ratings and a $408.58 price target, representing 89% upside potential. Key risks include premium valuation metrics (P/E 34.5), weak cash flow trends, and communications segment softness. The stock's current discount to analyst targets presents a compelling opportunity if execution improves.